Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Esophageal Squamous Cell Carcinoma Clinical Trials

19 recruiting trials for Esophageal Squamous Cell Carcinoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
19
Total Trials
19
Recruiting Now
4
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1 / Phase 2NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the...

Sponsor: Neonc Technologies, Inc.Enrolling: 1346 locations
RECRUITINGPhase 1NCT05799274

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors

Sponsor: Radiopharm Theranostics, LtdEnrolling: 92 locations
RECRUITINGNCT04510129

A Multicenter Cancer Biospecimen Collection Study

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor...

Sponsor: Cofactor Genomics, Inc.Enrolling: 16501 location
RECRUITINGPhase 1NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck,...

Sponsor: PfizerEnrolling: 31020 locations
RECRUITINGPhase 1NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have...

Sponsor: Seagen, a wholly owned subsidiary of PfizerEnrolling: 100620 locations
RECRUITINGPhase 2NCT05252078

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma...

Sponsor: Jiangxi Provincial Cancer HospitalEnrolling: 301 location
RECRUITINGPhase 2NCT07266493

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable...

This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin...

Sponsor: Shanghai Zhongshan HospitalEnrolling: 261 location
RECRUITINGNCT05028725

Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma

In the current protocol, we propose a study to evaluate a novel, combined esophageal sponge-methylation biomarker strategy for the early detection of esophageal squamous cell...

Sponsor: University of California, San FranciscoEnrolling: 2892 locations
RECRUITINGNCT06490003

Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma

Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The...

Sponsor: City of Hope Medical CenterEnrolling: 1501 location
RECRUITINGPhase 3NCT05495152

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node...

Sponsor: Henan Cancer HospitalEnrolling: 2192 locations
RECRUITINGPhase 2NCT06122493

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

This study aims to investigate a comprehensive therapeutic approach for patients with unresectable esophageal squamous cell carcinoma, clinically staged as Tany, N3, M0, and who...

Sponsor: Ruijin HospitalEnrolling: 481 location
RECRUITINGNCT06602843

Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy

The goal of this study was to explore the efficacy and safety of neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy in patients with locally...

Sponsor: Anhui Provincial HospitalEnrolling: 701 location
RECRUITINGPhase 3NCT04460352

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and...

Sponsor: Karolinska University HospitalEnrolling: 102012 locations
RECRUITINGPhase 2NCT06885814

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or...

This study was a single-center, single-arm, open-label phase II clinical trial. Thirty patients with unresectable locally advanced or postoperative recurrent esophageal squamous...

Sponsor: Nanfang Hospital, Southern Medical UniversityEnrolling: 301 location
RECRUITINGPhase 2NCT06509568

Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell...

Based on our previous single-arm Phase Ib study (CRIS trial, NCT06303583), we observed that neoadjuvant chemoradiotherapy followed by immunotherapy (nCRIT) significantly increased...

Sponsor: Zhejiang Cancer HospitalEnrolling: 921 location
RECRUITINGPhase 3NCT05919030

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced...

This study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. The subjects were untreated, unresectable locally advanced, recurrent or...

Sponsor: Renmin Hospital of Wuhan UniversityEnrolling: 1551 location
RECRUITINGPhase 2NCT07016724

Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer

Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the...

Sponsor: The First Affiliated Hospital of Zhengzhou UniversityEnrolling: 2081 location
RECRUITINGPhase 2 / Phase 3NCT06354530

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

The goal of this interventional study is to compare the safety and efficacy of neoadjuvant immunotherapy plus chemotherapy and anlotinib versus immunotherapy combined with...

Sponsor: Army Medical Center of PLAEnrolling: 2661 location
RECRUITINGPhase 3NCT06194734

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic...

Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.Enrolling: 4901 location

Frequently Asked Questions

There are currently 19 clinical trials for Esophageal Squamous Cell Carcinoma, with 19 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Esophageal Squamous Cell Carcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 4 Phase 3 trials for Esophageal Squamous Cell Carcinoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.